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without an increase in toxicity, and this improvement persisted after 7+3+/-5+2 (70% vs. 57%, p=0.08). There were no significant differences in overall survival and event-free survival in both arms but post-induction strategies were not standardized. These results substantiate the efficacy of FLAM induction in newly diagnosed AML. A phase 3 study is currently in development. This study is registered with ClinicalTrials.gov identifier: NCT01349972.
Introduction:
Adults with acute myeloid leukemia (AML) have a poor prognosis with conventional chemotherapy agents. There are approximately 18,000 new cases of AML with close to 11,000 deaths yearly in the United States. 1 Unfortunately, treatment of AML has changed little over the last 4 decades. "7+3" (7 days of continuous infusion (CI) cytarabine and 3 days of anthracycline)
remains the standard induction chemotherapy regimen for newly diagnosed non-acute promyelocytic leukemia (APL) AML patients who are fit for intensive therapy. 2 Despite many attempts to improve the 7+3 regimen with the addition and/or substitution of mechanistically diverse agents, no regimen has proven to be consistently superior to 7+3. 3 Timed sequential therapy (TST) has been shown to improve outcomes in some newly diagnosed adults and children with AML. [4] [5] [6] [7] [8] TST relies on the opportune timing of cell-cycle specific cytotoxic agents in order to exert maximal effect on leukemic cell death. In vitro studies of flavopiridol (alvocidib), a pan cyclin-dependent, multi-serine-threonine kinase inhibitor, followed by cytarabine in a TST manner demonstrated increased cytotoxicity compared to either agent alone. 9 FLAM (flavopiridol followed by cytarabine and mitoxantrone) was evaluated in 138 newly diagnosed poor-risk AML patients in serial phase 2 trials, with overall complete remission (CR) rates of 67-80% and reproducibly low rates of morbidity and mortality. [10] [11] [12] These data suggest that FLAM might improve outcomes relative to 7+3 induction therapy in newly diagnosed AML patients. Therefore, we sought to compare FLAM to 7+3 in a multicenter randomized phase 2 trial in newly diagnosed adult AML patients with intermediate and adverserisk cytogenetics.
Methods:
Further details on the Methods are provided in the Online Supplemental Appendix.
Patient eligibility:
Between May 2011 and July 2013, newly diagnosed AML patients 18-70 years with pathologic confirmation of bone marrow (BM) blasts >20% were enrolled in a multi-institutional study.
Eligibility criteria were similar to those from previous studies. [10] [11] [12] FISH for core-binding factor (CBF) AML (t(8;21); inv(16); (t(16;16)) was performed at each institution prior to enrollment, and patients were excluded if CBF positive. The study was conducted in accordance with the Declaration of Helsinki after approval by the ethics committee of each participating center.
Treatment:
Patients were randomized by REDCap 13 , a centralized computer-generated allocation procedure, All patients received a BM biopsy on day 14 unless medically contraindicated. Residual leukemia on day 14 was defined as BM blasts >5% morphologically with overall cellularity >10%. Arm B patients were eligible to receive an additional cycle of induction therapy, 5+2
(cytarabine 100 mg/m 2 /day CI IV days 1-5, daunorubicin 45 mg/m 2 IV days 1-2) in the setting of residual leukemia on day 14. Post-induction treatment was performed according to physician preference.
Response and toxicity:
BM aspirates and biopsies were performed before treatment, on day 14 of treatment, and at hematologic recovery or when leukemia regrowth was suspected. Response criteria were defined according to standard definitions. 14 Adverse events were graded by NCI Common Terminology
Criteria for Adverse Events (CTCAE), version 4.0.
Statistical analysis:
The study was designed to compare CR rates between FLAM and 1 cycle of 7+3, using a Secondary endpoints included toxicity comparisons, overall survival (OS), and event-free survival (EFS). OS was defined from date of randomization to death or last known follow-up.
EFS was defined as date of randomization to the first occurrence of persistent AML after 1 cycle of induction, relapse or death. Patients were censored for EFS if they had received non-protocol therapy or an allogeneic stem cell transplant (SCT). All significance tests for secondary endpoints were two-sided with a significance p value <0.05. To explore heterogeneity of treatment effects between various subgroups, logistic regression models with terms for treatment, the patient subgroup, and their interaction were fit. P values were derived from likelihood ratio tests and are considered exploratory. OS, EFS, and time to hematologic recovery probabilities were calculated using the Kaplan-Meier method and tested for differences between treatment arms with the log-rank test.
Results:
Patient characteristics:
One-hundred sixty-five patients (FLAM: n=109, 7+3: n=56) from 10 institutions were randomized, treated, and included in the analysis, as shown in Figure 1 . Clinical demographics and disease biological features of all patients are presented in and/or 3) Secondary AML.
Toxicity:
As depicted in 
Clinical outcomes:
FLAM led to a 70% CR rate (71 CR + 5 CRi; 95% CI: 60-78%), while 7+3 led to a 46% CR rate (25 CR + 1 CRi; 95% CI: 33-60%), odds ratio = 2.64, 95% CI: 1.29-5.45, one-sided p=0.003 (Table 3 ). The treatment effect was of similar magnitude and significance after controlling for the randomization stratification factors (odds ratio = 2.94, 95% CI: 1.44-5.99, one-sided p=0.001). Thirteen of 56 (23%) patients on the 7+3 arm received 5+2 for evidence of residual leukemia on day 14 (median % cellularity: 10%, range: 5%-50%; median % blasts: 33%, range:
12%-90%). Six of 13 (46%) patients achieved CR (including 1 CRi) after receiving 5+2. A comparison of CR rates between FLAM and 7+3+/-5+2 was 70% (95% CI: 60-78%) vs. 57%
(95% CI: 43-70%), respectively (one-sided p=0.08).
A day 14 BM biopsy was performed on 102/109 FLAM patients and 55/56 7+3 patients (Table   4 ). Residual leukemia on day 14 was significantly less with FLAM compared with 7+3 (25%, 95% CI: 17-35% vs. 44%, 95% CI: 30-58%, respectively; p=0.03). 
Subset analyses:
Although not powered to demonstrate significance, FLAM increased CR rates across different risk groups, as seen in exploratory ad-hoc analyses ( Figure 2 Figure 3B ).
Overall, 65 (60%) patients died on the FLAM arm compared with 32 (57%) deaths on the 7+3
arm. Causes of death on the FLAM arm included refractory leukemia (n=43), sepsis/infection (n=8), allogeneic SCT complications (n=6), hemorrhage/coagulopathy (n=3), TLS (n=2), stroke (n=1), multi-organ failure (n=1), and unknown causes (n=1); whereas causes of death on 7+3 included refractory leukemia (n=26), allogeneic SCT complications (n=4), TLS (n=1), and sepsis/infection (n=1). Additionally, 13 (17%) patients on FLAM died while in CR compared with 3 (10%) on 7+3. Causes of death in CR on FLAM included allogeneic SCT complications (n=6), infections (n=3; including 1 patient who died of E. coli sepsis during HiDAC consolidation), progressive bone marrow failure (n=1), presumed CNS leukemia (n=1), intracerebral hemorrhage (n=1), and unknown causes (n=1). Causes of death in CR on 7+3
included allogeneic SCT complications (n=2), and sepsis/infection (n=1).
Discussion:
The main study objective of this phase 2 trial was to assess the relative activity of FLAM compared with 7+3 in order to determine whether there was justification for further development of FLAM based on CR rate. The study findings support the hypothesis that FLAM induction leads to superior CR rates compared with 7+3 therapy (70% vs. 46%, p=0.003) in patients with intermediate and adverse-risk cytogenetics. The cycle 1 CR rate was chosen as a more specific indicator of relative activity between the 2 regimens because of variations in the approach following 1 cycle of induction therapy in practice. For instance, many leukemia clinicians utilize a re-induction strategy (i.e., 5+2) in some patients with persistent disease on day 14 after 7+3
induction. In contrast, FLAM is not intensified based on early BM biopsy findings. We felt that it was important to compare the FLAM regimen to an appropriate contemporary standard control regimen of 7+3; thus, we allowed a re-induction strategy (i.e., 5+2) in those patients with residual leukemia on day 14, as is recommended by the National Comprehensive Cancer Network Guidelines in AML. 18 There are a number of confounders that exist when determining whether to give a second cycle of induction such as patient age, performance status, toxicities, and day 14 bone marrow findings. 19 Therefore, a second cycle of induction was recommended, but not mandated, in those patients with residual leukemia on day 14. The comparison of FLAM to 7+3+/-5+2 (CR rates: 70% vs. 57%, p=0.08) also substantiates the improved efficacy with FLAM and supports further development of this regimen.
The CR rates seen on this study were lower than other recently reported phase 3 studies in AML due to differences in the patient populations studied. 16, 20, 21 Patients with favorable-risk cytogenetic features (i.e., CBF AML) were excluded on this study. Additionally, newly diagnosed elderly AML patients were included on this study up to age 70 years; whereas other trials only included patients up to 60 years of age. 16, 20, 21 Forty-seven percent of patients on this study had secondary AML, a subgroup with poor outcomes. 22 A larger proportion of patients had adverse-risk cytogenetics (41% total) when compared with other contemporary phase 3 studies in AML. 16, 20, 21 The relatively low CR rates seen on the 7+3 arm of this study were consistent with other recent reports in similar non-favorable risk patient populations. 23, 24 Importantly, overall toxicity was not different between FLAM and 7+3. TLS was a major concern given the high rates of TLS with flavopiridol in chronic lymphocytic leukemia 25-27 and consistent 7-10% incidence of grade >3 TLS in our prior phase 2 studies. [10] [11] [12] Three patients treated with FLAM on this study had grade 4 TLS, and 2 patients died due to complications of TLS. Patients with WBC >20,000/mm 3 , monocytic phenotypes (i.e., M4/M5, or arising from preexisting MPN), and baseline renal dysfunction appear to predispose to grade >4 TLS with FLAM. Though all patients received allopurinol and sevelamer prophylaxis, it may be necessary to use rasburicase and other supportive care measures to blunt cytokine release syndrome (e.g., steroids) in order to decrease the severity of TLS in future trials with FLAM.
Additionally, older age (>60 years) appears to predispose to FLAM toxicity. Although overall treatment-related mortality rates were similar between FLAM and 7+3, 8/11 early deaths (<60 days) on FLAM occurred in patients >60 years. On subset analyses, younger patients had higher CR rates with FLAM compared with 7+3, and this difference remained statistically significant after 7+3+/-5+2.
A major question in the management of AML patients is whether or not to give more chemotherapy for a day 14 BM biopsy revealing residual leukemia. There is, unfortunately, a lack of a consistent approach in managing these patients. Moreover, some patients with residual leukemia on a day 14 BM biopsy after 7+3 induction will ultimately achieve CR, and may not need additional induction therapy. [28] [29] [30] There is considerable investigator bias regarding whether or not to give a second cycle of induction therapy for patients with residual leukemia on day 14. 19 In our study, 24 patients on the 7+3 arm had residual leukemia on day 14, but only 13 (54%) received 5+2, and 6/13 (46%) achieved CR (versus 4/11 without 5+2). The proportion of patients achieving a CR with a 2 nd cycle of induction was similar to other reports. 16, 30 Although
Rowe et al. 31 reported that adults who achieve a CR after 1 or 2 courses of induction therapy have similar overall outcomes, this analysis was retrospective, and the patients included on this analysis received an identical course of induction therapy (i.e., 7+3), as opposed to 5+2 for day 14 residual leukemia. In contrast, the GOELAMS study group 32 performed a multicenter prospective study in which a second induction course was given to patients with >5% blasts on a day 15 BM biopsy, and showed that those with residual leukemia on day 15 had significantly worse outcomes, even after a second induction course. In the present study, patients on the FLAM arm did not receive more intensive therapy in the presence of residual leukemia on day 14, and a proportion of those (38%) still achieved CR.
Secondary AML represents a subgroup of patients with an extremely poor outcome who may benefit from FLAM induction. Secondary AML can be confirmed based on history alone in most cases. While 60% of patients with secondary AML in this current study achieved CR, we have now treated 158 newly diagnosed secondary AML patients with FLAM across all 4 phase 2 studies with an overall CR rate of 66% (105/158). [10] [11] [12] The similar effect with FLAM in secondary versus de novo AML highlights FLAM's activity in secondary AML, despite the overall decreased response rates and poor outcomes seen in this subpopulation. Moreover, although small numbers, all 6 patients with secondary AML and <50 years treated with FLAM achieved a CR on this study (compared to 1/3 patients with secondary AML and <50 years achieving a CR on 7+3). Thus, these data substantiate the benefit of FLAM in secondary AML, particularly in younger patients, and compare favorably to the promising findings seen with CPX-351. 23 Despite the significant improvement in response rates seen with FLAM, our study did not show an OS difference. These findings must be interpreted cautiously as the study was not powered to detect an OS difference. Other recently performed randomized studies in AML have also reported improved CR rates without OS advantage. 33 Moreover, lack of an OS advantage from a randomized phase 2 study aimed primarily to assess activity does not diminish the pertinence of these findings. It also reinforces the importance of a larger randomized phase 3 study specifically powered to detect an OS advantage, as evidenced by the finding that the OS of the 56 patients on the 7+3 arm of this poor-risk patient population was significantly better than the results of recently reported phase 3 studies. 16, 20, 21, 34 An additional limitation of the OS/EFS analyses on this study was the lack of standardized post-induction treatment strategies in both arms. FLAM was initially developed as 2 cycles (induction and consolidation therapy) in patients who achieve CR but post-induction treatment for both arms in this study was not defined. For example, only 46% of CR patients on FLAM received FLAM consolidation, while 28% received HiDAC, and 17% received early allogeneic SCT without consolidation therapy. Additionally, post-remission transplantation conditioning therapies and donor selections were also variable. This lack of a consistent treatment approach for patients who achieve CR is a major challenge in drug development in AML. It will be essential for these post-induction treatment strategies to be standardized for phase 3 studies in order to truly decipher whether FLAM induction can improve overall outcomes compared with 7+3. Given the inherent variability and unclear utility of a second cycle of induction with 7+3, a phase 3 study comparing FLAM to 1 cycle of 7+3 (without early re-induction therapy) would eliminate any potential biases of re-treatment. 1-There were no significant differences between both arms for all of the patient characteristics 2-Adverse genetics included patients with adverse cytogenetics according to ELN risk criteria 14 and/or FLT3-ITD mutations 3-Poor risk features defined by: 1) WBC >50,000/mm 3 , 2) Adverse genetics (adverse cytogenetics and/or FLT3-ITD mutation), 3) Secondary AML (treatment-related or AML from antecedent hematologic disorder) 1-2 early deaths due to TLS 2-1 early death due to TLS 3-1 early death due to GI bleed 4-3 early deaths due to sepsis No residual leukemia on day 14 76 (75%) 31 (56%) 0.03 Achievement of CR 63 (83%) 22 (71%) 1-P value derived from a two-sided Fisher's exact test and included for descriptive purposes only 2-7/109 patients on FLAM arm did not receive a day 14 BM biopsy due to:
Early death (n=4) Logistical concerns and/or patient refusal (n=2) Patient in Intensive Care Unit (n=1) 3-1/56 patients on 7+3 arm did not receive a day 14 BM biopsy due to: early death 4-Of the 24 patients on the 7+3 arm with residual leukemia on day 14: 10 (42%) achieved a CR (6/13 who received 5+2, 4/11 who did not receive 5+2).
Figure 1-Consort Diagram
172 patients were randomized between FLAM (n = 114) and 7+3 (n = 58), 109 patients on FLAM and 56 patients on 7+3 were analyzed for response and OS. 1-2 patients did not receive FLAM after randomization: progressive deterioration of performance status (n=1), exceeded maximum prior anthracycline dose (n=1) 2-2 patients did not receive 7+3 after randomization: withdrawal of consent (n=1), death before intervention (n=1) 3-3 patients were excluded from the analysis after initiating treatment with FLAM due to ineligibility: T-cell acute lymphoblastic leukemia (n = 1), Favorable-risk cytogenetics: t(8;21) (n = 1), Prior treatment for AML (n = 1) 4-7 patients treated with FLAM and 1 patient treated with 7+3 were non-evaluable (NE) for response due to early death.
Figure 2-Subset Analyses
Forest plot of odds ratios for complete remission in patient subgroups, plotted on a log scale. P values were derived from likelihood ratio tests of logistic regression models for interaction between treatment: (A) FLAM vs. 7+3 and (B) FLAM vs. 7+3+/-5+2, and patient subgroup on complete remission. To provide information about patients in the 'no poor-risk features' subgroup, 0.5 was added to all cell counts in this analysis for calculating odds ratios and 95% confidence intervals. 
Supplemental Data

Methods:
Patient Eligibility:
Inclusion Criteria:
• Adults >18 years and <70 years with pathologic confirmation of newly diagnosed AML (>20% bone marrow blasts)
• • ECOG performance status 0-3, patients > 65 years of age must have ECOG performance status < 2 prior to developing leukemic symptoms.
• Patient must be able to give informed consent
• Renal function: Serum creatinine < 2.0
• Hepatic enzymes (ALT, AST) < 5 x upper limit of normal unless leukemic infiltration • Total bilirubin < 2.0 mg/dl unless Gilbert's Disease, hemolysis or leukemia
• Left ventricular ejection fraction > 45%
Exclusion Criteria:
• Any previous treatment with flavopiridol
• Concomitant chemotherapy, radiation therapy, or immunotherapy
• Hyperleukocytosis with > 50,000 blasts/uL. Leukopheresis or hydroxyurea may be used immediately prior to study drug administration for cytoreduction. Must be stopped 24 hours before first dose of study chemotherapy.
• CBF AMLs associated with t(8;21) or M4eo subtype (inv [16] or t [16;16] ), as diagnosed by morphologic criteria, flow cytometric characteristics, and rapid cytogenetics or FISH or molecular testing.
• Acute Progranulocytic Leukemia (APL, M3)
• Active CNS leukemia
• Active, uncontrolled infection. Patients with infection under active treatment and controlled with antibiotics were eligible.
• Active, uncontrolled graft vs. host disease (GVHD) following allogeneic transplant for non-AML condition (e.g. MDS, lymphoid malignancy, aplastic anemia). Patients with GVHD controlled on stable doses of immunosuppressants were eligible.
• Presence of other life-threatening illness
• Patients with mental deficits and/or psychiatric history that preclude them form giving informed consent or from following protocol
• Pregnant and nursing patients were excluded.
Treatment:
Patients were randomized by REDCap 2 , a centralized computer-generated allocation 
Supportive care:
All patients received prophylaxis against tumor lysis syndrome (TLS) with allopurinol and a phosphate binder 24 hours prior to chemotherapy through day 8 of therapy.
Rasburicase was used to treat TLS per institutional policy. Prompt treatment with IV dexamethasone was performed for any patient with evidence of cytokine release syndrome. All patients received antibiotic prophylaxis against gram negative gastrointestinal infections, candidiasis, and herpes simplex virus. To prevent cytarabinerelated conjunctivitis, all patients received corticosteroid eye drops day 1 prior to initiation of cytarabine and continued for at least 7 days. Use of colony stimulating factors was not permitted.
Response and toxicity:
BM aspirates and biopsies were performed before treatment, on day 14 of treatment, and at hematologic recovery or when leukemia regrowth was suspected. Hematologic recovery was defined as absolute neutrophil count (ANC) >1,000/mm 3 and transfusionindependent platelet count >100,000/mm 3 . Response criteria were defined according to standard definitions. 1 Adverse events were graded by NCI Common Terminology
Statistical analysis:
The study was designed to compare CR rates between FLAM and 1 cycle of 7+3, using a Bayesian approach for interim monitoring for futility. The primary analysis would conclude a significant benefit for FLAM if the one-sided p value from a Fisher's exact test <0.10. A sample size of 165 patients, randomized 2:1 to FLAM or 7+3, respectively, yielded 85% power to detect an increase in the probability of CR from 55% with 7+3 3-5 to 75% with FLAM. In addition to the planned primary endpoint analysis, we also analyzed CR rates between FLAM and 7+3+/-5+2 by Fisher's exact test with a one-sided p value, analogous to the primary endpoint analysis. Interim monitoring for futility and toxicity, based on the probability of a statistically significant treatment difference if the study continued, was initiated after 45 patients received treatment and after each subsequent group of 30 patients were treated. Logistic regression was used to model CR as a function of treatment group and the randomization stratification factors (i.e., age >50 years, secondary AML and/or known adverse cytogenetics, and hyperleukocytosis).
Secondary endpoints included toxicity comparisons, overall survival (OS), and event-free survival (EFS). OS was defined from date of randomization to death or last known follow-up. EFS was defined as date of randomization to the first occurrence of persistent AML after 1 cycle of induction, relapse or death. Patients were censored for EFS if they had received non-protocol therapy or a SCT. Time to full hematologic recovery was defined for patients who achieved CR as the date of CR to date of recovery. All significance tests for secondary endpoints were two-sided with a significance p value <0.05. To explore heterogeneity of treatment effects between various subgroups, logistic regression models with terms for treatment, the patient subgroup, and their interaction were fit. P values were derived from likelihood ratio tests and are considered exploratory.
OS, EFS, and time to hematologic recovery probabilities were calculated using the
Kaplan-Meier method and tested for differences between treatment arms with the logrank test. Survival data was analyzed as of January 23, 2015. Analyses were completed with R version 3.1.1. 6 Statistical analysis was performed by ALB and GLR. All authors had access to the primary clinical trial data.
